| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5965525 | VICURON HOLDINGS | Cyclic peptide antifungal agents |
Feb, 2020
(4 years ago) | |
| US7709444 | VICURON HOLDINGS | Echinocandin pharmaceutical formulations containing micelle-forming surfactants |
Apr, 2021
(3 years ago) | |
| US6960564 | VICURON HOLDINGS | Echinocandin pharmaceutical formulations containing micelle-forming surfactants |
Apr, 2021
(3 years ago) | |
Eraxis is owned by Vicuron Holdings.
Eraxis contains Anidulafungin.
Eraxis has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Eraxis are:
- US5965525
- US7709444
- US6960564
Eraxis was authorised for market use on 17 February, 2006.
Eraxis is available in powder;intravenous dosage forms.
Eraxis can be used as treatment of fungal infections.
The generics of Eraxis are possible to be released after 22 September, 2023.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 22, 2023 |
Drugs and Companies using ANIDULAFUNGIN ingredient
Market Authorisation Date: 17 February, 2006
Treatment: Treatment of fungal infections
Dosage: POWDER;INTRAVENOUS
More Information on Dosage
ERAXIS family patents
